Novartis: Ovarian cancer drug disappoints in trial

May 27, 2010

(AP) -- Swiss drug maker Novartis AG said Thursday it won't ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing.

The drug, patupilone, failed to show improvements over existing drugs in 829 patients with advanced .

"Novartis does not plan to proceed with regulatory filings based on these data," the Basel-based company said.

Patupilone also is being tested for treatment of certain types of colorectal, lung and .

Shares in Novartis closed 1.6 percent higher at 51.85 Swiss francs ($45.01) in line with a general lift on the Zurich exchange.

shares

Related Stories

Recommended for you

Universal flu vaccine designed by scientists

September 30, 2016

An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Caliban
1 / 5 (1) May 27, 2010
What a drag for Novartis!!! Not only do they lose billions in profits, but they have that much less capital to live up to the double-digit quarterly dividend that their shareholders demand.
This kind of failure is inevitable for as long as BigPharma relies on the "Profit Foremost" model of drug development. Currently, if a drug candidate shows any promise(as in, can we rush this to market?), then it will be fast-tracked in preference to another that may show greater effectiveness, but may take longer to develop, refine, and trial.
If it's all about cashflow and marketing, then the quality of the product is going to suffer, and so I laugh every time I see them step on their own dick like this. Just imagine if you or I indulged in this sort of planning. It would be just as wise to use a casino visit to determine your budget.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.